Let’s delve into the details of each of the evaluated factors, but first, for a quick background: With a $917 Bil market cap, ...

TOPT's high concentration amplifies both potential returns and risks. See more on the pros and cons of iShares TOPT ETF vs.

Fantasy Impact: The backfield in New York should revert to a timeshare headed by veteran Tyrone Tracy in Skattebo's absence.

Eli Lilly is poised to become the first $1 trillion pharmaceutical company, driven by explosive growth in its weight-loss ...

Wall Street saw a mixed week, with the benchmark S&P 500 Index adding a marginal 0.08%, the NASDAQ Composite Index ...

AI breakthroughs in pharma are pushing Eli Lilly and healthcare stocks higher—and may soon reshape how we fight cancer.

Zacks Investment Ideas tracks market shifts as IWM strength, AI stock rotation and Nvidia's key support test shape year-end ...

Microsoft Corporation, Eli Lilly and Company, Oracle Corporation, Compagnie Financiere Richemont SA. Read 's Market Analysis on Investing.com ZA.

As the financial landscape continues to shift, investors find themselves on high alert, particularly with the tech sector experiencing recent declines. The CNBC Investing Club with Jim Cramer provides ...

Starting April 1, 2026, Medicare will begin covering Lilly’s leading weight loss drug, Zepbound, along with Mounjaro, at $245—a 55% discount from current net prices, according to Leerink Partners.

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...

The next generation of weight loss drugs will hit the market in 2026. Eli Lilly and Novo Nordisk are racing to the finish ...